These observations support further investigation into the use of CXCR4 inhibitors and/or PLC modulators as a rational preventive strategy to limit the occurrence of resistance and improve the efficacy of Dex and chemotherapy in patients with B-ALL. The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.